Dr. Vizesi has over 20 years of experience in orthobiologics and spinal fusion, holding leadership roles at Orthofix, SeaSpine and NuVasive, according to an April 16 press release.
He is passionate about driving progress in therapeutics and bringing new technologies to surgeons that deliver improved outcomes for patients, according to the news release. He most recently served as Orthofix’s chief scientific officer.
In his new role, Dr. Vizesi will work alongside the clinical and regulatory team to aid in the successful execution of the OsteoAdapt clinical study program and navigate the FDA approval process.
He will also support Theradaptive’s ongoing label expansion into sports medicine, dental and craniomaxillofacial indications.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.